CLINICAL VERSUS FIXED WARFARIN DOSING AND THE ADDED EFFECT OF A GENOTYPE GUIDED ALGORITHM ON WARFARIN DOSE PREDICTION IN ARABS
Date
2025-01Metadata
Show full item recordAbstract
Warfarin prescribing has been a challenge due to the need for frequent monitoring. Commonly, warfarin is prescribed using a fixed warfarin dosing method (FWD). Genotype guide warfarin dosing (GWD) is a method that uses genetic and clinical factors to guide warfarin dosing, whereas clinical warfarin dosing (CWD) uses clinical factors alone. GWD was compared to CWD or FWD and showed promising results. It is unknown how the non-GWD methods compare to one another. Additionally, the effect of GWD on the Arab population is not well studied.
A three-phase project was conducted. The first phase was a prospective clinical study with a historical control comparing CWD to FWD in a group of Arab patients. The Gage et al. algorithm was used to calculate warfarin dose in the CWD arm. No difference was seen between the CWD and FWD in terms of the mean percentage of time in the therapeutic range (62.2 ± 26.2% vs. 58 ± 25.4%, p=0.2). In the second phase, saliva samples were collected from the previous project, and the following genetic variants were genotyped: VKORC-1639G>A, CYP2C9*2, CYP2C9*3, and CYP4F2*3. Those with at least one reduced function allele required a significantly lower median (IQR) weekly dose compared to the normal function allele [24.5 (15.3) mg/week vs. 35 (29.8) mg/ week, p=0.006]. Similar results were seen in variants of VKORC-1639G>A. In the third phase, patients were randomized to a derivation (67%) and a validation cohort. Using univariate and multiple regression analyses, factors affecting warfarin dose were identified, and a regression equation model was developed. The model could explain 56% of warfarin dose variability. Using the validation cohort, the model had a significantly lower median absolute error when compared to the Gage et al. algorithm (9.1 vs 10.8, p=0.02).
In conclusion, the results show that FWD and CWD produced similar outcomes, and if pharmacogenetic testing is not available, either method can be utilized. Additionally, variants of VKORC-1639G>A and CYP2C9 but not CYP4F2*3 were associated with warfarin dose in the Arab population. The use of the derived model was more accurate in predicting warfarin dose compared to an internationally validated algorithm.
DOI/handle
http://hdl.handle.net/10576/62791Collections
- Master in Pharmacy [62 items ]
Related items
Showing items related by title, author, creator and subject.
-
Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review
Fahmi, Amr Mohamed; Elewa, Hazem; El Jilany, Islam ( Springer , 2022 , Article Review)Background For decades, vitamin K antagonists and specifically warfarin, have been the sole agents used orally to manage thromboembolic conditions, including stroke and venous thromboembolism (VTE). Several factors lead ... -
Evaluation of pharmacist-based compared to doctor-based anticoagulation management in Qatar
Elewa, Hazem; Jalali, Fatemeh; Khudair, Nada; Hassaballah, Noha; Abdelsamad, Osama; Mohammed, Shaban... more authors ... less authors ( Blackwell Publishing Ltd , 2016 , Article)Rationale, aims and objectives For over 60 years, warfarin has been the mainstay anticoagulant used in the outpatient setting for the prevention and treatment of a wide variety of thromboembolic clinical conditions. ... -
The impact of genetic and non-genetic factors on warfarin dose prediction in MENA region: A systematic review
Bader, Loulia Akram; Elewa, Hazem ( Public Library of Science , 2016 , Article Review)Background Warfarin is the most commonly used oral anticoagulant for the treatment and prevention of thromboembolic disorders. Pharmacogenomics studies have shown that variants in CYP2C9 and VKORC1 genes are strongly and ...